[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
8-Feb-2010

[ | E-mail ] Share Share

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
@jclinicalinvest

Marker of Ewing sarcoma: Potential new drug target?

Ewing sarcoma (EWS) is a bone tumor of unknown cellular origin that affects children and young adults. The protein CD99 is highly expressed in most cases of EWS, but its function in the disease is unknown. Now, Katia Scotlandi and colleagues, at SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy, have identified a crucial role for CD99 in the development of EWS and suggest that targeting CD99 or its downstream molecular pathway may be a new therapeutic approach for EWS.

In the study, decreasing CD99 expression in human EWS cell lines reduced their ability to form tumors xenografted into mice. In vitro, it increased expression of H-neurofilament, a marker of neuronal differentiation. Consistent with this, an inverse correlation between CD99 expression and H-neurofilament expression, neural differentiation, and oncogenic transformation was observed in patient-derived EWS cells. The authors therefore conclude that CD99 prevents neural differentiation and suggest that blocking it might provide a new approach to treating EWS.

###

TITLE: CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis

AUTHOR CONTACT:
Katia Scotlandi
SSN Emilia Romagna Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy.
Phone: 39.051.6366760; Fax: 39.051.6366763; E-mail: katia.scotlandi@ior.it.

View this article at: http://www.jci.org/articles/view/36667?key=24e370e9a7cd8f56b36b



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.